AMMF’s Response to NHS England’s Draft Commissioning Policy re SIRT for Intrahepatic Cholangiocarcinoma

NHS-funded SIRT (selective internal radiation therapy) had been available for patients with intrahepatic cholangiocarcinoma through the CtE (Commissioning through Evaluation) programme until this funding was withdrawn on 31st March 2017 ‘to be evaluated’. In June 2018, NICE issued their draft Interventional Procedures Guide (IPG) for comment regarding the safety and efficacy of intrahepatic chola...

Read More

ENS-CCA Congress, Rome, 21-23 June

AMMF is a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA¹), and was very pleased to be invited to attend the second ENS-CCA congress in Rome, 21 to 23 June 2018. More than 180 participants attended this congress, all dedicated to working towards improving the future for those with cholangiocarcinoma. During the three very busy days, 36 studies were presented, including 8 o...

Read More

AMMF’s Response to NICE Recommendations re SIRT for Intrahepatic Cholangiocarcinoma

NICE (National Institute for Health and Care Excellence) are currently consulting on the safety and efficacy of SIRT (selective internal radiation therapy) for intrahepatic cholangiocarcinoma, and have made their draft recommendations available for comment. To see the draft recommendations, click here               These latest draft recommen...

Read More

ABC-03 clinical study results published in British Journal of Cancer

"Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial" Results from the ABC-03 clinical study have been published in the British Journal of Cancer (21.06.18). Dr Alison Backen, Systemic Therapy Research Project Manager in Medical Oncology at The Christie NHS Foundation Trust, explains the study and the findings for AMMF:  ...

Read More

Cholangiocarcinoma-UK

Following the Cholangiocarcinoma Workshop organised and hosted by Professor Nigel Heaton on Friday 19th January, Dr Shahid Khan introduced the Cholangiocarcinoma-UK group to the audience. The mission statement for Cholangiocarcinoma-UK, a group affiliated to the British Association for the Study of Liver Disease (a BASL Special Interest Group) is: “Cholangiocarcinoma-UK is a multi-disciplinary gro...

Read More

New! The AMMF Cholangiocarcinoma Scholarship

AMMF is delighted to announce The AMMF Cholangiocarcinoma Scholarship, a three-year PhD award.   The first of these three-year AMMF funded PhD studentships is specifically to investigate the role of mutations in bile duct cancer (cholangiocarcinoma). The successful PhD student will be based at The Boulter Lab, located in the MRC Human Genetics Unit at the University of Edinburgh.  The Boulter lab is r...

Read More

AMMF launches ‘Our CC Family – Your Story’

            For the past five years during each February, Cholangiocarcinoma Awareness Month, AMMF has run a daily Guest Post feature on Facebook, which has proved to be extremely important to our supporters. Over those years, the response to this feature has grown enormously and, because of the limitation of the number of days in the month, we know that ...

Read More

Now Published! The MDT: Cholangiocarcinoma Patients’ Observations

“The multidisciplinary team meeting in the UK from the patients’ perspective: comments and observations from cholangiocarcinoma patients and their families”   The thoughts of cholangiocarcinoma patients and their families on what they understood an MDT meeting to be, and their experiences around such meetings, were the basis of a paper by AMMF CEO Helen Morement, which has now been publis...

Read More

The Cancer52 CNS Report

Through their work, Clinical Nurse Specialists (CNS) can bring invaluable support and humanity to the treatment and care of their patients. To demonstrate the importance of their work, and how it can improve the quality of life for patients diagnosed with the rare and less common cancers, Cancer52¹ have produced a report: “Clinical Nurse Specialists working with people with rare and less common...

Read More

AMMF joins European Reference Network (Rare-Liver)

AMMF is now a representative and advocate for cholangiocarcinoma patients within ERN-RARE-LIVER, the rare hepatic disease section of the European Research Networks. ERN RARE-LIVER is looking to connect expert centres across Europe, including the UK, to improve access to diagnosis, treatment and high quality care for patients with rare liver diseases. To find out more about the work of the ERNs click...

Read More